SEARCH

SEARCH BY CITATION

References

  • 1
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
  • 2
    Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206.
  • 3
    Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
  • 4
    Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, et al. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011;46:929-937.
  • 5
    Bronowicki JP, Hezode C, Bengtsson L, Pol S, Bourlière M, Serfaty L, etal. 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon, and ribavirin in the Prove2 trial. J Hepatol 2012;56(Suppl 2A):1094.